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ABSTRAK 
 
Satu kajian hirisan lintang telah dilaksanakan bertujuan mengenalpasti prevalens dan 
distribusi genotip virus papiloma manusia (HPV) di kalangan pesakit prakanser 
(neoplasia intraepitelial serviks gred 3 atau CIN 3) dan kanser serviks invasif (ICC), di 
Pusat Perubatan UKM (PPUKM). Blok tisu benaman parafin dari tahun 1999 ke 2007 
dikenalpasti dari Jabatan Patologi, PPUKM. Sebanyak 80 rekod perubatan (20 CIN 3  
dan 60 ICC) dengan informasi lengkap telah dikumpul untuk data klinikopatologi. Dari 
kanser invasif (n=60), karsinoma sel skuamus (SCC) terdiri dari 75% dan 
adenokarsinoma 25%. Purata umur pesakit ialah  52.0 ± 12.21 tahun dan wanita Cina 
merupakan etnik yang tertinggi (66.3%). Sebanyak 12 jenis genotip HPV telah 
dikenalpasti iaitu HPV 16, 33, 18, 39, 52, 45, 58, 59, 31, 35, 6 dan 11. Prevalens 
infeksi HPV ialah setinggi 92.5% dengan genotip 16 yang paling kerap ditemui 
(73.8%), diikuti dengan genotip 33 (30%) dan genotip 18 (22.5%). Sebanyak 31 kes 
(38.8%) menunjukkan kehadiran satu jenis genotip HPV sahaja, manakala 44 (53.8%) 
menunjukkan kehadiran genotip HPV berganda (dua genotip atau lebih). Pada ICC, 
HPV 16, 33, 18, 52 dan 39 merupakan lima jenis HPV yang paling kerap ditemui. 
Infeksi HPV yang tinggi dan infeksi berganda merupakan perkara utama ditemui pada 
lesi CIN 3 dan kanser serviks. 
 
Kata kunci: virus papiloma manusia (HPV), kanser serviks, genotip HPV, distribusi   
                   HPV, prevalens HPV 
 
ABSTRACT  
 
A cross sectional study was done to determine the prevalence and distribution of 
human papillomavirus (HPV) genotypes in pre-invasive (cervical intraepithelial 
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neoplasia, grade 3 or CIN 3) and invasive cervical cancer (ICC), in Universiti 
Kebangsaan Malaysia Medical Centre (UKMMC). A total of 80 paraffin-embedded 
tumour tissue blocks (20 CIN 3, 60 invasive cancers) between 1999 to 2007 were 
retrieved from the archives of the Department of Pathology.  Patient’s medical records 
were obtained from the Medical Records Office. Among invasive cancers (n=60), 
squamous cell carcinoma (SCC) account for 75% and adenocarcinoma 25%. The 
mean age of cases studied was 52.0 ± 12.2 years and Chinese was the predominant 
ethnicity (66.3%). Twelve HPV genotypes were identified, namely, HPV 16, 33, 18, 39, 
52, 45, 58, 59, 31, 35, 6 and 11. The prevalence of HPV was 92.5% with types 16 
being the most common (73.8%), followed by types 33 (30%) and 18 (22.5%). A total 
of 31 cases (38.8%) showed single HPV genotype, while 43 (53.8%) had multiple HPV 
(two genotypes or more) genotypes.  In ICC, HPV 16, followed by types 33, 18, 52 and 
39 were the top five common HPV genotypes detected. High prevalence of HPV and 
multiple HPV infections were major findings among patients with pre-invasive and 
invasive cervical cancer. 
 
Key words:  Human papillomavirus (HPV), cervical cancer, HPV genotype, HPV 
distribution, HPV prevalence 
 
 
INTRODUCTION 
 
Cervical cancer is the second most 
common cancer among women 
worldwide. The WHO (2002) reported 
that in 2002, over 471,000 new cases 
were diagnosed and 288,000 women 
died from cervical cancer worldwide. The 
incidence and mortality rate of cervical 
cancer were higher in developing 
countries (Sankaranarayanan et al. 
2001), where no effective, systematic 
and organised screenings are carried 
out. It is recommended that for a 
screening method to be effective, it must 
be targeted on high risk women once or 
twice in their lifetime using a sensitive 
method (Sankaranarayanan et al. 2001) 
and a high enough coverage of more 
than 80% of targeted population.  
The Ministry of Health (MOH) Malaysia 
reported cervical cancer as the second 
leading cause of death after breast 
cancer among women in year 2003 
(Malaysian National Cancer Registry 
2003) with an age-standardised 
incidence of 19.7 per 100,000 population. 
Its incidence rate by ethnicity was 
highest among Chinese women, 
intermediate among the Malays and 
lowest among Indians. In the third 
Malaysian National Health Morbidity 
Survey (NHMS 3) 2006, 43.7% women 
were reported to have undergone Pap 
smear examination with highest 
prevalence among Chinese women 
(50.5%), other Bumis (Sabahans, 
Sarawakians) (45.5%), Malays (43.6%), 
Indian (37.2%) and others (24.7%). The 
cost of screening and managing pre and 
invasive cervical cancer (ICC) in 
Malaysia is calculated to be RM 250 
million per year (Wan Puteh et al. 2008). 
The human papillomavirus (HPV) is 
considered a public health problem as 
the virus is sexually transmitted (Kjaer et 
al. 2001; Lehtinen et al. 2002; Jastreboff 
& Cymet 2002) and is a major risk factor 
for cervical cancer development 
worldwide (Reid & Lörincz 1996). The 
International Agency for Research in 
Cancer (IARC) in 1995 reported that 
HPV type 16 and 18 are carcinogenic to 
human. However, more than 100 types of 
HPV have been discovered (Krejci & 
Sanchez 2005; Jastreboff & Cymet 
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2002), of which approximately 15 are 
oncogenic. Another 30 types of HPV are 
associated with ano-genital tract 
infections (Krejci & Sanchez 2005) and 
type 18 is also found in inverted 
papilloma and papillary transitional cell 
carcinoma of the bladder (Chan et al. 
1997). Cervical co-infection with multiple 
types of HPV was postulated to be a 
predictor of acquisition and persistence 
of HPV infections and subsequent 
development of cancer (Rousseau et al. 
2001). The prevalence of HPV among 
normal population (Clifford et al. 2005) 
shows that it varies greatly between 
populations, from 1.4% in Spain to 25.6% 
in Nigeria.  
HPV types within a species are related, 
e.g. the Alpha 7 species consists of HPV 
18, 39, 45, 59, 68, 70 and a novel c85. 
Alpha 9 consist of types 16, 31, 33, 35, 
52, 58 and 67. The Alpha 10 species 
consists of the low risk types 6, 11, 13, 
44, 55, 74, PcPV and CCPV (De Villiers 
et al. 2004). HPV infections especially 
types 16 and 18 (Dillner et al. 1997) are 
necessary but not sufficient causes of 
cervical cancer (Yadav et al. 1997; 
Samoff et al. 2005). Other external 
cofactors or host factors are required for 
progression to cancer. There are many 
risk factors contributing to cervical 
cancer, these include multiple sexual 
partners; early sexual debut and activity 
at a younger age (Nor Hayati 2003); high 
parity (Hinkula et al. 2004); genital 
infection e.g. with Chlamydia trachomatis 
(Hakama et al. 2000; Samoff et al. 2005); 
herpes simplex virus (Lehtinen et al. 
2002); chemical carcinogens (oral 
contraceptive drugs, cigarette smoking) 
and low socioeconomic status (Nolte & 
Walczak 2000). The development of 
cervical cancer is common in older 
women even though the HPV infections 
usually occur in the younger age group 
(Sellors et al. 2003). In the African 
region, the mean age of invasive cervical 
cancer (ICC) among patients was 33.9 
years (±11.4 years) compared to 
Southern Europe  which is 56.5 years 
(±14.3 years) (Bosch et al. 1995).  
HPV genotypes have been found to be 
geographically determined.  A previous 
local study showed that HR HPV 
genotypes were detected in 95% 
abnormal smears with HPV 16 being the 
most prevalent HPV genotype identified 
(Sharifah et al. 2009). In Europe (Clifford 
et al. 2005), the prevalence of HPV 16 
among women was higher, compared 
with sub-Saharan Africa, while in 
Washington, type 16 dominated followed 
by type 18 (Schwartz et al. 2001), and 
this follows the general world trend.  
The distribution of HPV types worldwide 
showed the same result as Schwartz et 
al. (2001), except for an earlier study 
from Indonesia in which HPV type 18 
was reported to be the predominant type 
(Bosch et al. 1995). However, this study 
was later replicated using a bigger 
sample, and results showed that HPV 
positivity was as high as 96% 
(Schellekens et al. 2004) with types 16 
(44%), 18 (39%) and 52 (14%) being the 
top three dominant types. A study by 
Chichareon et al. (1998) in Thailand 
showed that HPV type 16 was most 
commonly found in squamous cell 
carcinoma (SCC), followed by HPV types 
18, 58, 52, 31, 33 and 39. Bosch and de 
Sanjosě (2003) also showed that the 
prevalence of HPV in SCC was around 
80% and the five common HPV 
genotypes found are 16, 18, 45, 31 and 
33.     
From Hong Kong, HPV epidemiology 
demonstrated a high prevalence of type 
52 (Cheung et al. 2008). In Iran, in 
addition to the predominant types 16/18, 
there was also a high prevalence of type 
33 (Mortazavi et al. 2002). These studies 
showed that following infection with HPV 
type 16 and 18, some other types are 
also predominant and this may vary by 
regions. This inconsistency raises the 
question as to whether Malaysia has its 
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own particular HPV distribution that is not 
in trend with the rest of the world. The 
different HPV genotypes may translate 
into different risks of acquiring cervical 
cancers according to geographical 
distributions.  
With the introduction of the HPV 
vaccines (quadivalent and bivalent), the 
protection against cervical cancer is 
tremendous. The quadrivalent vaccine 
that protects against types 6, 11, 16 and 
18 has the potential to prevent vulval, 
vaginal and cervical cancers as well as 
genital warts. There is evidence of cross 
protection by the quadrivalent vaccine 
against similar genotypes in the same 
tree (Bosch et al. 2008). In a cross 
protection study by Brown (2007), the 
efficacy of the quadrivalent HPV vaccine 
against CIN 2, 3 or adenocarcinoma in 
situ associated with HPV types 6, 11, 16, 
18 was 100%, but with increase in 
numbers of HPV types 31, 33, 34, 45, 51, 
52, 56, 58, 59, the efficacy of the vaccine 
reduces to 38%. 
Elucidation of HPV genotypes in 
Malaysian women has not been done on 
a major scale.  This study aims to 
determine the prevalence and distribution 
of HPV genotypes in a cohort of 
Malaysian patients with preinvasive and 
invasive cervical cancer from Universiti 
Kebangsaan Malaysia Medical Centre 
(UKMMC) 
 
MATERIALS AND METHODS 
 
A total of 80 (20 CIN 3, 45 SCC and 15 
adenocarcinoma) formalin-fixed, paraffin 
embedded tumour tissue (PET) blocks 
were retrieved from the Department of 
Pathology, Universiti Kebangsaan 
Malaysia Medical Centre (UKMMC) 
between 1999 to 2007.  Patient consent 
was obtained through telephone 
interviews. 
Five µm thick sections were cut from 
each case. Gloves and blades were 
changed during sectioning to avoid cross 
contamination between samples. DNA 
was extracted using DNeasy Blood and 
Tissue Kit (QIAGEN, Germany, Catalog 
No. 69506). Tissue sections were 
deparaffinized with xylene and alcohol 
according to the manufacturer’s protocol. 
Samples were lysed using proteinase K. 
Lysates were loaded onto DNeasy spin 
columns. After two washings, pure DNA 
was eluted in low salt buffer. Presence of 
DNA was determined by 1% agarose gel 
electrophoresis. The optical density (OD) 
measurement was done to determine the 
purity and concentration of DNA within a 
ratio of 1.7 to 2.0.  The extracted DNA 
was stored in   -20 °C until RT-PCR. 
HPV genotyping was carried out using 
SACACE HPV High Risk Typing Real-TM 
kit (SACACE, Italy, Catalog No. TV26-
100FRT). This kit is an in-vitro Real Time 
amplification test for qualitative detection 
and genotyping of 12 HR-HPV genotypes 
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 
and 59). It contains four PCR-mix tubes; 
each of which contain primers directed 
against regions of three HPV genotypes 
with the β-Globin gene as an internal 
control. Multiplex amplification reaction 
was performed in a volume of 13 μl 
containing 8 μl of reaction mix (PCR-mix-
1, PCR-buffer FRT, Hot Start DNA 
Polymerase) and 5 μl of DNA sample. 
Each reaction was run for 45 cycles, 
under the following conditions: 15min at 
95ºC, 20 sec at 95ºC and 60 sec at 60ºC. 
Data obtained from Real-Time PCR is 
then keyed-in to a software (Microsoft® 
Excel HPV Typing Real-Time MX Results 
Matrix.xls) provided by the SACACE kit, 
and interpreted.  Statistical analysis was 
performed using Microsoft® Excel 2007. 
 
RESULTS 
 
A total number of 80 PET samples were 
analyzed (20 CIN 3, 45 SCC and 15 
adenocarcinoma). The mean age of 
patients was 52 years, ranging from 30 to 
80 years (Table 1). The highest number 
Med & Health 2010; 5(2): 66-76  Sharifa Ezat  W.P. et al. 
 
 70 
Table 1: Prevalence of HPV genotypes in CIN 3 
and invasive cervical cancer by age group, (n=80) 
 
Age group n (%) 
30-39 12 15 
40-49 19 23.8 
50-59 26 32.5 
≥ 60 23 28.8 
Total 80 100 
 
Table 2: Prevalence of HPV genotypes in CIN 3 
and invasive cervical cancer, (n=80) 
 
Ethnic n (%) 
Malay 20 25 
Chinese 53 66.3 
Indian 4 5.0 
Others 3 3.8 
Total 80 100 
 
of HPV positive cases were from the 50-
59 year age group (32.5%) with the 
Chinese showing the highest prevalence 
(66.3%) followed by Malay (25%) and 
Indian (5%) (Table 2). 
Of the 80 samples of preinvasive and 
invasive cervical cancer (ICC), 92.6% 
showed presence of HPV genotypes. 
Twelve different HPV genotypes were 
detected i.e 16, 18, 31, 33, 35, 39, 45, 
52, 58, 59, 6 and 11. Among the CIN 3 
cases, HPV 16 was the most prevalent 
(60%), followed by HPV 33 (35.0%), HPV 
45 (25.0%), HPV 18 (15.0%) and HPV 39 
(15.0%). HPV 16 (80.0%) was the most 
prevalent genotype in SCC of the cervix, 
followed by HPV 45 (54.5%), HPV 33 
(31.1%), and HPV 52 (26.7%). The 
prevalent HPV genotypes in 
adenocarcinoma of the cervix were HPV 
16 (73.3%), 18 (46.7%), 33 (20.0%), 39 
(6.7%) and 59 (6.7%) (Table 3). The five 
most prevalent HPV genotypes in 80 
samples of preinvasive and ICC were 
HPV 16 (73.8%), 33 (30.0%), 18 
(22.5%), 39 (16.3%) and 52 (16.3%) 
(Figure 1). The five most prevalent HPV 
genotypes in ICC were 16 (78.3%), 33 
(28.3%), 18 (25%), 52 (20%) and 39 
(16.7%) (Figure 2). 
Multiple infections of at least two HPV 
genotypes were noted in 53.8% of the 
cases. 38.8% showed presence of a 
single genotype while 31.3% had two 
genotypes, 12.5% had three genotypes, 
5% had four genotypes and 5% had five 
genotypes. Multiple HPV genotypes were 
more prevalent (53.8%) than single HPV 
genotype (38.8%) (Table 4).  
 
DISCUSSION 
 
The higher prevalence of HPV in 
Chinese ethnicity among sampled 
patients diagnosed to have cervical 
cancer in this study was consistent with 
results from the Malaysian Cancer 
Registry (2003) which reported that the 
incidence are highest among the 
Chinese with 28.8 per 100,000, followed 
by Indians (22.4) and Malays (10.4). 
Even though samples were from 
UKMMC which is a public teaching 
hospital, with a high number of Malay 
patients, results showed that the highest 
percentage of cervical cancer was found 
in the Chinese patients (66.3%). Malays 
(25%) and Indians (5.0%) showed lower 
prevalence of cervical cancer in this 
study. This result reflects the findings of 
cervical cancer incidence at the National 
level. In a Muslim country, and coming 
from a Malay culture that strictly prohibits 
cohabitation or sex outside wedlock may 
have a role in the reduction of risky 
sexual behaviours among its youths. 
Findings from the National Health 
Morbidity Survey 3 (NHMS 3) 2006 
showed that an estimated proportion of 
those who had genital discharge/ulcers 
and who subsequently came forward for 
treatment were Chinese (49.9%). The 
prevalence profile of those who had
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Table 3: Distribution of HPV genotypes in CIN 3 and invasive cervical cancer, (n=80) 
 
CIN 3 SCC Adenocarcinoma Total 
HPV genotypes 
n (%) n (%) n (%) n (%) 
HPV 16 12 (60.0) 36 (80.0) 11 (73.3) 59 (73.8) 
HPV 18 3 (15.0) 8 (17.8) 7 (46.7) 18 (22.5) 
HPV 31 1 (5.0) 0 (0) 0 (0) 1 (1.3) 
HPV 33 7 (35.0) 14 (31.1) 3 (20.0) 24 (30.0) 
HPV 35 0 (0) 1 (2.2) 0 (0) 1 (1.3) 
HPV 39 3 (15.0) 9 (20.0) 1 (6.7) 13 (16.3) 
HPV 45 5 (25.0) 6 (54.5) 0 (0) 11 (13.8) 
HPV 52 1 (5.0) 12 (26.7) 0 (0) 13 (16.3) 
HPV 58 2 (10.0) 1 (2.2) 0 (0) 3 (3.8) 
HPV 59 0 (0) 1 (2.2) 1 (6.7) 2 (2.5) 
HPV 6 0 (0) 1 (2.2) 0 (0) 1 (1.3) 
HPV 11 0 (0) 1 (2.2) 0 (0) 1 (1.3) 
Total HPV genotypes* 34  90  23  147  
No. of cases with HPV Infection 18 (90.0) 43 (95.6) 13 (86.7) 74 (92.5) 
No. of cases without HPV infection 2 (10.0) 2 (4.4) 2 (13.3) 6 (7.5) 
Total no. of cases 20  45  15  80  
*Samples with one or more HPV genotypes 
CIN 3: Cervical Intraepithelial Neoplasia 3 
SCC: Squamous Cell Carcinoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  Prevalence of HPV genotypes in CIN 3 and invasive cervical cancer, (n=80) 
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Figure 2:  Prevalence of HPV genotypes in invasive cervical cancer, (n=60) 
 
genital discharge/ulcer was highest 
among the Indians (3.5%) followed by 
Chinese (2.9%) and Malays (1.7%) 
(NHMS 3 2006).  
Results of this study did not show any 
association between age and HPV 
positivity, and numbers of HPV types. In 
a study by Tang (2002), age was found 
to be inversely associated with HPV 
infections. Young females were more 
likely to harbour HPV, and oncogenic 
HPVs were found in patients below the 
age of 61 years old. Women in this study 
were from the middle age to elderly age 
groups with a mean age at 52 ± 12.2 
years. In this study, 28.8% cases aged 
60 and above, presented in the later 
stages of cancer. The Durex sexual 
survey (1999) and Sexual and 
Reproductive Health of Adolescents and 
Youths in Malaysia (2005), showed that 
sexual debut for women in this country 
was highest among the 17-18 year old. 
During adolescence, the knowledge of 
early sex and its’ risk management is 
poor. NHMS 3 (2006) showed that the 
knowledge on symptoms of sexually 
transmitted illness was low, (50.9-53.8%) 
especially among the younger age group 
(below 19 years old) and the extreme 
age (above 70 years old). Findings from 
the NHMS 3 (2006) showed that females 
had their first sexual intercourse at the 
age of 22.8 years and initiation of sex 
does not vary much by ethnicity. 
However, this is an understatement as 
young adolescents do not declare sexual 
initiations to parents and guardians 
openly. This sexual novelty of a young 
woman with usually a more mature and 
experienced partner, puts her at risk of 
acquiring the infection through sexual 
intercourses and transmission to other 
partners later on. Data on the HPV pre- 
 
Table 4: Prevalence of single and multiple HPV 
genotypes in CIN 3 and invasive cervical cancer, 
(n=80) 
 
No. of HPV genotypes n (%) 
Negative 6 7.4 
Single 31 38.8 
Two 25 31.3 
Three 10 12.5 
Four 4 5.0 
Five 4 5.0 
Total 80 100 
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valence and types of HPV among men is 
not readily available, and the cost 
effectiveness of HPV vaccination among 
men are still debated. The development 
of infection takes time, sometimes up to 
decades (Sankaranarayanan et al. 2001) 
with most clearing the infection within 
one year (Sellors et al. 2003). Women 
usually become infected when they are 
younger (Rousseau et al. 2001; Clifford 
et al. 2005), and some infections do not 
clear and progresses into dysplasia and 
frank cancer. HPV 16 infection (new 
infections) was associated with an 
increased risk of acquisition of other HPV 
types (Rousseau et al. 2001) and 
increases the risk of ICC (Dillner et al. 
1997). By this time the women are 
usually in their older age group. From 
this study, we noted the presence of 
cancer among ‘relatively younger’ 
women i.e. less than 52 years old (mean 
age of cases in this study). Multiple 
infections play a role in oncogenesis and 
reduce cellular resistance, thus 
accelerating progression to cancer. In the 
30-39 year age group, 41.7% had 
developed CIN 3, 75% had infection with 
type 16, 16.7% had infection with type 18 
and 33.3% showed type 33. A high 
percentage of multiple infections was 
also noted in the younger age group.  
Vinh-Hung et al. (2007) reported that 
SCC accounted for two thirds of the 
incidence of cervical cancer in the United 
States. Our results showed HPV types 
16, 18, 33 and multiple infections 
dominated in SCC. Type 18 was also 
found at a high percentage in 
adenocarcinoma (46.7%). Both types 16 
and 33 are from the Alpha 9 species, 
while type 18 is from the Alpha 7 
species. Our results also showed that 
HPV positivity in ICC was highest in SCC 
(95.6%).  
Lehtinen et al. (2002) in their study 
among SCC, showed that HPV type 16, 
18 and 33 were associated with ICC 
especially types 33 and 16. According to 
Tang (2002) oncogenic HPV types are 
less infectious but cause more persistent 
infections than their lower risk 
counterparts, thus, repeated exposures 
are needed for infection to occur.  
Clifford et al. (2005) reported that HPV 
16 was twice as frequent as any other 
high-risk type in all regions except the 
sub-Saharan Africa where HPV 35 was 
equally common. The next common 
types were type 33 and 56 in Asia, 58 in 
South America and 31 in Europe. In our 
patients with CIN 3 and ICC, the 
prevalence of HPV 16 was found to be 
as high as 73.8%.  
These current findings showed that 
types 16 and 18 play a dominant role in 
cervical carcinogenesis, both globally as 
well as in Malaysia.  However, the high 
prevalence of HPV type 33 is a deviation 
against the normal trend except in Iran 
(Mortazavi et al. 2002), where the 
common HPV that predominate are types 
16, 18 followed by 33. In the Iranian 
study, the prevalence of HPV in ICC was 
85.5% which is nearly as high as the 
findings from our study which was 
93.3%. Banura et al. (2008) reported that 
among the 12-24 year old sexually active 
women, the prevalence of HPV 
genotypes by decreasing order are 52, 
51, 18 and 16. Other studies have also 
reported similar results (Clifford et al. 
2005) in which type 33 and 56 are 
common among Asian women.  
HPV 16/18 vaccines are estimated to 
provide about 67% protection against 
ICC in Asia (Bao et al. 2007). The 
difference in the prevalence of HPV 
types by different regions is shown in a 
mass study of women by Bao et al. 
(2007); by decreasing frequencies: HPV 
16, 18, 58, 52, 33 in East Asia (China, 
Hong Kong, Taiwan, Korea, Japan); HPV 
45, 52, 58 in South-East Asia; and HPV 
45, 33 and 35 in South Central Asia (Bao 
et al. 2007). The difference in the HPV 
prevalence need to be considered before 
mass vaccination of women is carried 
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out, if the prevalence of HPV is not within 
the bivalent or quadrivalent vaccine 
efficacy coverage. However, results from 
our HPV genotyping suggests that a 
vaccine that covers both HPV types 16 
and 18 will be able to cover 54.9% of this 
disease. 
From our study of preinvasive and ICC, 
HPV type 16 was the most prevalent type 
detected (73.8%), followed by type 33 
(30%) and type 18 (22.5%). With the 
different variations seen and different 
infectivity rates reported from various 
countries and regions, it is very important 
that local genotypes be properly 
determined and elucidated. The results 
of our study, reflect the prevalence and 
distribution of HPV genotypes in a cohort 
of Malaysian patients with preinvasive 
and ICC.  
 
CONCLUSION 
 
HPV infection is very high among high 
grade preinvasive lesions and ICC 
(92.5%) in Malaysian women. The five 
most prevalent HPV types are HPV 16, 
33, 18, 39 and 52. Multiple HPV 
infections (53.8%) are relatively common 
compared to single infections. If the 
same HPV types represent the country’s 
HPV infection trends among local high 
risk or cancer inflicted women, a vaccine 
that prevents infections from HPV types 
16 and 18 will protect as high as 54.9% 
of women in this society. 
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